Reported 8 months ago
Eternal Eternal Biotech, backed by the resources of the Eternal Group, has established a solid operational foundation in the domestic animal medicine market and expanded its operations overseas. The surge in pet ownership due to factors like the COVID-19 pandemic, declining birth rates, and aging populations has attracted many local companies to invest in pet medicine. Eternal Eternal International Biotech, with its roots in medications for economic animals like pigs and poultry, is a leader in this trend, aiming to focus 30% of its operations on pet medicine in the future. Leveraging its experience, reputation, and product line accumulated over nearly 30 years in animal medicine, Eternal Eternal is poised to significantly increase its contribution to revenue through the development of pet medications and health supplements.
Source: YAHOO